JonathanMerleLehmanMD

Summary

• Dr. Jonathan Lehman is excited to join the extraordinary research and clinical faculty community at Vanderbilt University Medical Center in medical oncology. His clinical and research interests center on the treatment of thoracic malignancy, including small cell lung cancer (SCLC), the most aggressive lung carcinoma. Dr. Lehman is a physician-scientist and Harrison Society Scholar with a focus on neuroendocrine malignancy, tumor heterogeneity, and signaling. He has over a decade of research experience ranging from studying transgenic maize gene regulation at the USDA National Center for Agricultural Utilization Research (NCAUR) to genetically epilepsy prone rat models and vanadium peroxidase chemistry. He earned his MD and PhD from the University of Alabama School of Medicine at Birmingham, and his thesis work focused on the role of a novel organelle, the primary cilium, in the regulation of developmental pathways involving growth, cell migration, wound healing, and differentiation in the hair and skin. He brings his developmental biology background to novel target discovery and treatments in lung cancer including the biology of chemotherapy resistance in SCLC, as well as somatostatin receptor and neuroendocrine signaling. Dr. Lehman completed his residency in internal medicine and fellowship in medical oncology at Vanderbilt University Medical Center and is dedicated to improving the care and outcomes of lung cancer patients through basic and translational research. Dr. Lehman is a United States Department of Education Presidential Scholar, Congressional Barry M. Goldwater Scholar, 2015 American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator, and 2016 LUNGevity Foundation Career Development Awardee.